Ra Capital Management, L.P. bought $423.8M of Parabilis Medicines (PBLS)
Executed Jun 11, disclosed Jun 15, 4 days later.
Over the 21 trading sessions from the disclosed entry session (Jun 15), the stock returned +11.6% (delay-adjusted); from the execution session (Jun 11), -1.2%. Derived: entry at the session's open, exit at the close 20 sessions later.
Ra Capital Management, L.P. (Director) filed 31 Form 4 reports as a reporting entity in the trailing twelve months (23 purchases, 8 sales, 1 filed past the two-business-day deadline), most often in Artiva Biotherapeutics, Inc. (ARTV). Across 22 priced purchase filings, the average 21-session return was +16.2% from execution and +14.2% from disclosure (delay-adjusted; derived). The largest single filing was $423.8M of PBLS (21,188,750 sh across 2 lots, as filed), executed Jun 11.
Healthcare · Parabilis Medicines, Inc. operates as a clinical-stage biopharmaceutical company focused on developing helical peptide therapeutics for dis…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→244,593 sh across 6 lots
Exec Jul 20
Filed Jul 22 · 4:55 PM ET